

S26-6 Usefulness of therapy of Wilson's disease with zinc acetate: Correlation with efficacy and pharmacokinetics of copper and zinc

○Masataka SHIMOKAWA¹, Toshihide ENDO¹, Jin SHIOMURA¹

¹Nobelpharma Co., Ltd.

Wilson's disease is an autosomal recessive disorder with copper metabolism caused by mutations in the ATP7B gene. Zinc therapy is effective for the treatment of Wilson's disease, which is reported by Brewer et al. Zinc acetate formulation was approved as a Wilson's disease therapeutic drug, firstly in USA (1997), thereafter in Euro-countries, and zinc now becomes the standard medicine for maintenance therapy of the Wilson's disease. In Japan, Nobelpharma conducted clinical trials for Wilson's disease on the request of the Japan Pediatric Society and the patient association, and with its good results, submitted NDA and received its approval in 2008. A long term clinical study for a large number of Wilson's disease patients with zinc formulations have not been reported so far in Japan. Here we are happy to present data on the results of efficacy of zinc acetate formulation treatment, together with detailed zinc pharmacokinetics in 23 patients with Wilson's disease.